Back to search results

FOCUS Study: Using a Mobile App for Oral Chemotherapy

This study, called FOCUS, is looking at how cancer patients use a mobile app called EveryDose to help them take their oral (by mouth) cancer medications as prescribed. You might be able to join if you are 18 or older, can read English or Spanish, have a blood or solid tumor cancer, and are starting an oral anti-cancer drug for the first time. The study wants to see how many people agree to use the EveryDose app, how consistently they use it, and how well they take their medication over 12 weeks. The study is currently unclear on its recruitment status and plans to enroll 25 participants.

Study design
This is an interventional study with 25 planned participants. It is not specified if it is randomized or blinded.
What's involved
Participants will use the EveryDose mobile application for up to 10 minutes daily, for up to 12 weeks, at home. The app will send alerts to remind you to take your medication and to log when you take it.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for up to 12 weeks to measure app usage and medication adherence.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06952790

Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Study

Recruiting
NAAges 18+InterventionalSupportive care
University of Miami
~25 participants
Updated 2026-08-28 on ClinicalTrials.gov
What's tested:EveryDose Mobile Application

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of patients who agree to use the EveryDose application
Measured over up to 12 weeks
+2 more outcomes measured

Conditions

Cancer

Explore related trials

Hematologic NeoplasmSolid Neoplasm

NCT06952790

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Miami

    Miami, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Frank Penedo, PhD · PRINCIPAL_INVESTIGATOR · University of Miami

Who to contact

Jessica MacIntyre, DNP
[email protected]
305-243-4570
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Any sex/gender Able to provide written informed consent
Able to read/understand English or Spanish
Diagnosis of hematologic or solid tumor cancer diagnosis
Prescribed an oral anti-cancer drug as monotherapy treatment for the first time by their treating oncologist.
Internet access on a smartphone, tablet, or computer

Exclusion

Less than 18 years of age
Unable to provide written informed consent
Unable to read/understand English or Spanish
History of dementia or major psychiatric disease that would interfere with study participation
Prior treatment with an oral anti-cancer treatment
Participating in another clinical trial during the time of screening.

What this trial measures

  • Percentage of patients who agree to use the EveryDose applicationup to 12 weeks

    Percentage of patients who agree to use the EveryDose application

  • EveryDose application adherence measured by percentageup to 12 weeks

    The percentage of weeks out of 12 week-period that the patient used the App (\> 50%)

  • Medication Adherence measured by dose ratioup to 12 weeks

    Will be measured by the ratio of doses taken to the doses prescribed over a given time period.